Weill Cornell Nanoparticles Drive 4 of 10 Prostate Cancer Remissions in Mice as Immunity Surges
Updated
Updated · Cornell Chronicle · Jun 15
Weill Cornell Nanoparticles Drive 4 of 10 Prostate Cancer Remissions in Mice as Immunity Surges
3 articles · Updated · Cornell Chronicle · Jun 15
Summary
Four of 10 mice with aggressive prostate cancer had complete or near-complete remissions and indefinite survival when Weill Cornell’s prostate-targeted C’ dots were combined with immune checkpoint blockade; adding CSF-1R blockade raised complete remissions to 5 of 10.
The amorphous silica nanoparticles killed tumors directly by pushing cancer cells into ferroptosis and turned prostate tumors from immunologically “cold” to “hot,” boosting T cells, macrophages and other antitumor immune activity.
PSMA targeting steered the particles to prostate tumor cells, and researchers reported no toxicity in healthy tissues, including the spleen, where the particles briefly accumulated.
The preclinical Cancer Research study builds on C’ dots already in advanced-phase trials for image-guided surgery and therapeutic uses, supporting further safety and efficacy testing in human clinical trials.
The therapy failed in 50% of cases. What makes some tumors resistant to this nanoparticle attack?
This new therapy cured half the mice. What's the biggest hurdle to replicating that success in human trials?
Could these iron-delivering nanoparticles make other 'cold' tumors vulnerable to immunotherapy?
C' Dots Nanoparticles Reprogram Immune Microenvironment for Durable Prostate Cancer Remission in Preclinical Study
Overview
Researchers at Weill Cornell Medicine and Cornell Engineering have introduced a new approach for treating prostate cancer using specialized nanoparticles called C' dots. These nanoparticles work in two important ways: they directly eliminate prostate tumor cells and also reshape the immune system to fight cancer more effectively. By creating conditions that support a stronger antitumor immune response, C' dots help overcome the challenge of achieving lasting results where traditional immunotherapies have struggled. This dual action prepares the immune system to better recognize and attack cancer cells, unlocking new potential for durable remission in prostate cancer.